WallStreetZenWallStreetZen

NYSEMKT: IGC
Igc Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IGC

Based on 1 analyst offering 12 month price targets for Igc Pharma Inc

Min Forecast
$4.50+1,013.86%
Avg Forecast
$4.50+1,013.86%
Max Forecast
$4.50+1,013.86%

Should I buy or sell IGC stock?

Based on 1 analyst offering ratings for Igc Pharma Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IGC stock forecasts and price targets.

IGC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-26

1 of 1

Forecast return on equity

Is IGC forecast to generate an efficient return?

Company
-98.61%
Industry
118.06%
Market
270.29%
IGC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IGC forecast to generate an efficient return on assets?

Company
-75.46%
Industry
36.52%
IGC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IGC earnings per share forecast

What is IGC's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.06
Avg 2 year Forecast
-$0.07

IGC revenue forecast

What is IGC's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$1.3M-0.83%
Avg 2 year Forecast
$1.5M+14.17%
IGC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IGC revenue growth forecast

How is IGC forecast to perform vs Biotechnology companies and vs the US market?

Company
6.85%
Industry
288.79%
Market
58.75%
IGC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IGC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IGC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IGC$0.40$4.50+1,013.86%Buy
MURA$2.10N/AN/A
EVAX$5.75$13.50+134.78%Strong Buy
RNTX$1.55$10.00+545.16%Buy
GBIO$5.57$10.67+91.51%Buy
View Top Biotech Stocks

Igc Pharma Stock Forecast FAQ

Is Igc Pharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: IGC) stock is to Buy IGC stock.

Out of 1 analyst, 0 (0%) are recommending IGC as a Strong Buy, 1 (100%) are recommending IGC as a Buy, 0 (0%) are recommending IGC as a Hold, 0 (0%) are recommending IGC as a Sell, and 0 (0%) are recommending IGC as a Strong Sell.

If you're new to stock investing, here's how to buy Igc Pharma stock.

What is IGC's earnings growth forecast for 2026-2027?

(NYSEMKT: IGC) Igc Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 40.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 100.43%.

Igc Pharma's earnings in 2025 is -$6,342,000.On average, 3 Wall Street analysts forecast IGC's earnings for 2026 to be -$5,330,495, with the lowest IGC earnings forecast at -$5,167,038, and the highest IGC earnings forecast at -$5,539,356.

In 2027, IGC is forecast to generate -$5,993,401 in earnings, with the lowest earnings forecast at -$5,811,783 and the highest earnings forecast at -$6,229,505.

What is IGC's revenue growth forecast for 2026-2027?

(NYSEMKT: IGC) Igc Pharma's forecast annual revenue growth rate of 6.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 288.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.75%.

Igc Pharma's revenue in 2025 is $1,327,000.On average, 2 Wall Street analysts forecast IGC's revenue for 2026 to be $119,504,791, with the lowest IGC revenue forecast at $115,963,236, and the highest IGC revenue forecast at $124,226,865.

In 2027, IGC is forecast to generate $137,575,805 in revenue, with the lowest revenue forecast at $133,489,395 and the highest revenue forecast at $143,024,351.

What is IGC's forecast return on assets (ROA) for 2026-2027?

(NYSEMKT: IGC) forecast ROA is -75.46%, which is lower than the forecast US Biotechnology industry average of 36.52%.

What is IGC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IGC price target, the average IGC price target is $4.50, with the highest IGC stock price forecast at $4.50 and the lowest IGC stock price forecast at $4.50.

The Wall Street analyst predicted that Igc Pharma's share price could reach $4.50 by Aug 26, 2026. The average Igc Pharma stock price prediction forecasts a potential upside of 1,013.86% from the current IGC share price of $0.40.

What is IGC's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: IGC) Igc Pharma's current Earnings Per Share (EPS) is -$0.07. On average, analysts forecast that IGC's EPS will be -$0.06 for 2026, with the lowest EPS forecast at -$0.06, and the highest EPS forecast at -$0.06. In 2027, IGC's EPS is forecast to hit -$0.07 (min: -$0.06, max: -$0.07).

What is IGC's forecast return on equity (ROE) for 2026-2027?

(NYSEMKT: IGC) forecast ROE is -98.61%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.